Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MedSci Healthcare Holdings Limited
梅斯健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2415)

VOLUNTARY ANNOUNCEMENT
SUCCESSFUL BIDDING OF LARGE-SCALE REAL-WORLD STUDY ON "INTELLIGENT GOUT MANAGEMENT PROJECT" FOR A CHINESE PHARMACEUTICAL COMPANY

This is a voluntary announcement made by MedSci Healthcare Holdings Limited (the "**Company**" and together with its subsidiaries, the "**Group**") to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that recently, Shanghai MedSci MedTech Co., Ltd., a subsidiary of the Company, was successfully awarded a bid for a project in respect of a large-scale real-world study by a Chinese pharmaceutical company, which aims to "systematically evaluate the efficacy and safety of IL-1β monoclonal antibody therapy in patients with acute and intercritical gout through a combined prospective and retrospective observational study", with a project value of approximately RMB21 million.

Leveraging over a decade of experience in its internet-based physician platform and utilizing big data and artificial intelligence technologies to link physicians, patients and pharmaceutical and medical device companies, the Group provides digital solutions that empower the healthcare ecosystem and enhance medical quality.

By order of the Board
MedSci Healthcare Holdings Limited
Zhang Fabao
Executive Director and Chairman

Hong Kong, 25 September 2025

As at the date of this announcement, the Board of the Company comprises Dr. Zhang Fabao, Dr. Li Xinmei, Mr. Wang Shuai and Mr. Cheng Liang as executive Directors; Ms. Wang Xin and Mr. Yan Shengfeng, as non-executive Directors; and Ms. Liu Tao, Mr. Yu Mingyang and Mr. Lau Yiu Kwan Stanley, as independent non-executive Directors.